Antibody-based therapeutics development

ADCs, BsAbs, and BsADCs improved with efficacy and safety

Under development of antibody-based therapeutics suitable to indication and target

에디스바이오텍 개발 흐름에디스바이오텍 개발 흐름
  • 단클론 항체 치료제

    Monoclonal antibody

    • Targeting novel tumor associated antigens
  • 항체-약물 결합 치료제

    Antibody-drug conjugates, ADCs

    • Improved efficacy and safety
    • Toxins, Radioisotope, etc.
  • 이중 항체 치료제

    Bispecific antibody

    • Synergistical effects by dual targeting
    • Overcome drug resistance and improve efficacy
  • 이중 항체-약물 접합체

    Bispecific antibody-drug conjugate

    • Improved cancer cell selectivity, internalization, payload release

The potential of ADCs to overcome the limitation of current cancer therapies

새로운 암 치료 가능성과 효율성을 높인 ADC
  • Next-generation drug maximizing the advantages of 1st to 3rd generation of anti-cancer therapies

    ADC enables to overcome the unwanted non-specific killing of normal and cancer cells caused by traditional chemotherapy

  • Providing new treatment opportunities for cancer patients with limited options

    Safe and maximized anti-cancer effects through selective delivery of drugs to target cancer cells

Strengths in the development of ADCs by antibody asset companies

  • ADC approvals and clinical studies

    • 14 approved drugs and over 300 clinical trials ongoing in 2023

      Experience has been accumulated in linker and payload development.
  • Securing antibodies for disease-selective targets: The key to successful ADC development

    • Patents for approved ADC linkers and payloads are expiring

    • Opportunities for ADC development by securing novel antibodies

      ED2 pipeline is based on our proprietary tumor targeting antibody combined with proven linker and payloads
  • Strengths in the development of ADCs by antibody asset companies

    • First in Class drug development

      Use linkers and payloads that have already been confirmed to be safe for new antibodies
    • Low biological risk, low competition, and low probability of clinical trial failure